Your browser doesn't support javascript.
Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study.
Smadja, David M; Bonnet, Guillaume; Gendron, Nicolas; Weizman, Orianne; Khider, Lina; Trimaille, Antonin; Mirault, Tristan; Fauvel, Charles; Diehl, Jean-Luc; Mika, Delphine; Philippe, Aurelien; Pezel, Théo; Goudot, Guillaume; Sutter, Willy; Planquette, Benjamin; Waldmann, Victor; Sanchez, Olivier; Cohen, Ariel; Chocron, Richard.
  • Smadja DM; Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.
  • Bonnet G; Department of Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Paris, France.
  • Gendron N; F-CRIN INNOVTE, Saint-Étienne, France.
  • Weizman O; Paris Cardiovascular Research Center (PARCC), INSERM, Université de Paris, Paris, France.
  • Khider L; Center Hospitalier Universitaire de Bordeaux, Hôpital Cardiologique Haut-Lévêque, Unité Médico-Chirurgical de Valvulopathies et Cardiomyopathies, Pessac, France.
  • Trimaille A; Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.
  • Mirault T; Department of Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Paris, France.
  • Fauvel C; Paris Cardiovascular Research Center (PARCC), INSERM, Université de Paris, Paris, France.
  • Diehl JL; Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy, Vandoeuvre les Nancy, France.
  • Mika D; Department of Vascular Medicine, AP-HP, Georges Pompidou European Hospital, Paris, France.
  • Philippe A; Nouvel Hôpital Civil, Center Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France.
  • Pezel T; Paris Cardiovascular Research Center (PARCC), INSERM, Université de Paris, Paris, France.
  • Goudot G; Department of Vascular Medicine, AP-HP, Georges Pompidou European Hospital, Paris, France.
  • Sutter W; Rouen University Hospital, FHU REMOD-VHF, Rouen, France.
  • Planquette B; Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.
  • Waldmann V; Medical Intensive Care Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Paris, France.
  • Sanchez O; INSERM, Université Paris-Saclay, Chatenay-Malabry, France.
  • Cohen A; Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.
  • Chocron R; Department of Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Paris, France.
Front Med (Lausanne) ; 8: 747527, 2021.
Article in English | MEDLINE | ID: covidwho-1497093
ABSTRACT

Background:

Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown.

Objectives:

To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagulation (AC) among patients with COVID-19 hospitalized in medical wards. Methods and

results:

We used a large French multicentric retrospective study enrolling 2,878 COVID-19 patients hospitalized in medical wards. After exclusion of patients who had an AC treatment before hospitalization, we generated a propensity-score-matched cohort of patients who were treated with intermediate-dose or standard-dose prophylactic AC between February 26 and April 20, 2020 (intermediate-dose, n = 261; standard-dose prophylactic anticoagulation, n = 763). The primary outcome of the study was in-hospital mortality; this occurred in 23 of 261 (8.8%) patients in the intermediate-dose group and 74 of 783 (9.4%) patients in the standard-dose prophylactic AC group (p = 0.85); while time to death was also the same in both the treatment groups (11.5 and 11.6 days, respectively, p = 0.17). We did not observe any difference regarding venous and arterial thrombotic events between the intermediate dose and standard dose, respectively (venous thrombotic events 2.3 vs. 2.4%, p=0.99; arterial thrombotic events 2.7 vs. 1.2%, p = 0.25). The 30-day Kaplan-Meier curves for in-hospital mortality demonstrate no statistically significant difference in in-hospital mortality (HR 0.99 (0.63-1.60); p = 0.99). Moreover, we found that no particular subgroup was associated with a significant reduction in in-hospital mortality.

Conclusion:

Among COVID-19 patients hospitalized in medical wards, intermediate-dose prophylactic AC compared with standard-dose prophylactic AC did not result in a significant difference in in-hospital mortality.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.747527

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.747527